TR200300478T2 - Hümanize antiLT-ß-R antikorları - Google Patents

Hümanize antiLT-ß-R antikorları

Info

Publication number
TR200300478T2
TR200300478T2 TR2003/00478T TR200300478T TR200300478T2 TR 200300478 T2 TR200300478 T2 TR 200300478T2 TR 2003/00478 T TR2003/00478 T TR 2003/00478T TR 200300478 T TR200300478 T TR 200300478T TR 200300478 T2 TR200300478 T2 TR 200300478T2
Authority
TR
Turkey
Prior art keywords
humanized
antibodies
antilt
antibodies humanized
humanized antilt
Prior art date
Application number
TR2003/00478T
Other languages
English (en)
Inventor
Garber Ellen
Lyne Paul
W. Saldanha Jose
Original Assignee
Biogen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc. filed Critical Biogen Inc.
Publication of TR200300478T2 publication Critical patent/TR200300478T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LT- -R'ye insancillastirilmis antikorlar ve bunlarin kullanim metodu saglanmistir.
TR2003/00478T 2000-10-13 2001-10-12 Hümanize antiLT-ß-R antikorları TR200300478T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
TR200300478T2 true TR200300478T2 (tr) 2004-10-21

Family

ID=27399340

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2006/02095T TR200602095T2 (tr) 2000-10-13 2001-10-12 Hümanize Anti-LT-Beta-R antikorları
TR2003/00478T TR200300478T2 (tr) 2000-10-13 2001-10-12 Hümanize antiLT-ß-R antikorları

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2006/02095T TR200602095T2 (tr) 2000-10-13 2001-10-12 Hümanize Anti-LT-Beta-R antikorları

Country Status (25)

Country Link
US (2) US7429644B2 (tr)
EP (1) EP1326897A2 (tr)
JP (1) JP2004532608A (tr)
KR (1) KR20030041164A (tr)
CN (1) CN1547590A (tr)
AR (1) AR035352A1 (tr)
AU (2) AU2002211747B2 (tr)
BG (1) BG107802A (tr)
BR (1) BR0114646A (tr)
CA (1) CA2425809A1 (tr)
CZ (1) CZ20031307A3 (tr)
EA (1) EA006945B1 (tr)
EE (1) EE200300179A (tr)
GE (1) GEP20063752B (tr)
HU (1) HUP0302573A2 (tr)
IL (1) IL155340A0 (tr)
IS (1) IS6779A (tr)
MX (1) MXPA03003144A (tr)
NO (1) NO20031642L (tr)
NZ (1) NZ525793A (tr)
PL (1) PL366307A1 (tr)
SK (1) SK5672003A3 (tr)
TR (2) TR200602095T2 (tr)
WO (1) WO2002030986A2 (tr)
YU (1) YU28503A (tr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
WO2004002431A2 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoyin beta receptor antibodies
JP2006515750A (ja) * 2002-12-20 2006-06-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療
MXPA05006663A (es) * 2002-12-20 2005-09-30 Biogen Idec Inc Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CA2560742A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CA2624393C (en) 2005-11-04 2016-01-05 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
JP5420399B2 (ja) * 2006-05-25 2014-02-19 グラクソ グループ リミテッド 改変型ヒト化抗インターロイキン−１８抗体
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
WO2008063776A2 (en) * 2006-10-12 2008-05-29 Genentech, Inc. Antibodies to lymphotoxin-alpha
SG154441A1 (en) * 2006-10-20 2009-08-28 Biogen Idec Inc Treatment of demyelinating disorders
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
MY157948A (en) 2006-11-02 2016-08-30 Genentech Inc Humanized anti-factor d antibodies
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
SI2158315T1 (sl) 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
CN107108720A (zh) 2014-11-06 2017-08-29 豪夫迈·罗氏有限公司 具有改变的FCRN结合的Fc区变体及其使用方法
CR20180097A (es) 2015-07-14 2018-05-25 Immunext Inc Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
AU2020401755A1 (en) 2019-12-11 2022-08-04 Cilag Gmbh International Multispecific binding molecules comprising LTBR and EDB binding domains and uses thereof
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
AU2022423749A1 (en) 2021-12-20 2024-06-13 F. Hoffmann-La Roche Ag Agonistic ltbr antibodies and bispecific antibodies comprising them
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH06501456A (ja) 1990-06-27 1994-02-17 バイオジェン，インコーポレイテッド 表面複合リンホトキシン
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE397665T1 (de) 1992-12-04 2008-06-15 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
EP0809510B1 (en) * 1995-01-26 2004-06-09 Biogen, Inc. Lymphotoxin-alpha/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
BR9908214A (pt) 1998-01-30 2000-11-28 Biogen Inc Tratamento para linfomas foliculares utilizando inibidores da via da linfotoxina (lt)
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
WO2004002431A2 (en) 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoyin beta receptor antibodies
JP2006515750A (ja) 2002-12-20 2006-06-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療
MXPA05006663A (es) 2002-12-20 2005-09-30 Biogen Idec Inc Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.

Also Published As

Publication number Publication date
KR20030041164A (ko) 2003-05-23
JP2004532608A (ja) 2004-10-28
YU28503A (sh) 2006-05-25
SK5672003A3 (en) 2003-10-07
NZ525793A (en) 2008-04-30
AU1174702A (en) 2002-04-22
CA2425809A1 (en) 2002-04-18
WO2002030986A2 (en) 2002-04-18
EP1326897A2 (en) 2003-07-16
NO20031642L (no) 2003-06-13
BR0114646A (pt) 2006-02-21
IL155340A0 (en) 2003-11-23
IS6779A (is) 2003-04-11
US20090092601A1 (en) 2009-04-09
AR035352A1 (es) 2004-05-12
AU2002211747B2 (en) 2007-11-29
US7429644B2 (en) 2008-09-30
TR200602095T2 (tr) 2007-02-21
MXPA03003144A (es) 2004-12-06
EA006945B1 (ru) 2006-06-30
EA200300464A1 (ru) 2003-10-30
NO20031642D0 (no) 2003-04-10
HUP0302573A2 (hu) 2003-10-28
PL366307A1 (en) 2005-01-24
US20040058394A1 (en) 2004-03-25
WO2002030986A3 (en) 2003-03-13
BG107802A (bg) 2004-01-30
EE200300179A (et) 2003-08-15
CZ20031307A3 (cs) 2003-10-15
GEP20063752B (en) 2006-02-27
CN1547590A (zh) 2004-11-17

Similar Documents

Publication Publication Date Title
TR200602095T2 (tr) Hümanize Anti-LT-Beta-R antikorları
CY2019029I2 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ATE264863T1 (de) 28-epirapaloge
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
CY2014038I2 (el) Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ZA200206266B (en) Antibodies that bind human interleukin-18 and methods of making and using.
EE200100336A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
EE201200006A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
ITMI20011986A0 (it) Metodo e composizione per l'attivazione di cellule presentanti l'antigene
EA200201214A1 (ru) Замещенные тиоацетамиды
DE60140516D1 (de) Behandlung von fluorkohlenstoff- ausgangsmaterialien
NO20031860D0 (no) Kahalaolid F
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
BR0110577A (pt) Decorina transgenicamente produzida
BR0110902A (pt) Inibidores de mmp-9/mmp-2
FI20000194A0 (fi) Menetelmä kaupankäynnissä
DE60139694D1 (de) Menschliche myelom zelllinie
MY133881A (en) "calcilytic compounds"
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies
BR0316544A (pt) Compostos calcilìticos
NO20005548D0 (no) Mykobakterieinhibitorer
DE60113535D1 (de) Kompositionen und verwendungen von cgi-69
ATE256754T1 (de) Gerbstoff-/nachgerbstoffpräparationen